Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.
Interventions
DRUGFaster-acting insulin aspart
0.2 U/kg body weight injected subcutaneously (under the skin)
DRUGinsulin aspart
0.2 U/kg body weight injected subcutaneously (under the skin)
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Type 1 or type 2 diabetes mellitus for more than 12 months * Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for 12 months or longer for subjects with type 1 diabetes and for 3 months or longer for subjects with type 2 diabetes * Body Mass Index (BMI) between 18.0-32.0 kg/m2 (both inclusive)
Exclusion criteria
* Surgery or trauma with significant blood loss (more than 500 mL) within the last 3 months prior to trial start * Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) * Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the blood glucose concentration-time curve | from 0-2 hours |
Secondary
| Measure | Time frame |
|---|---|
| Area under the blood glucose concentration-time curve | from 0-6 hours |
Countries
United States
Outcome results
None listed